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To my family 
In the middle of difficulty lies opportunity 
Albert Einstein, 1879-1955 
  
ABSTRACT 
Skeletal muscle is a primary site of insulin action and insulin-stimulated glucose 
transport and occupies a center stage in maintaining whole body glucose and lipid 
homeostasis. Another key feature of a healthy skeletal muscle is its ability to switch 
between utilization of lipids and glucose as fuel in response to feeding or fasting 
respectively. This metabolic flexibility is impaired in skeletal muscle from insulin 
resistant and type 2 diabetic patients. Key molecules such as AMP Kinase [AMPK] and 
Pyruvate Dehydrogenase Kinase [PDK] play a crucial role in maintaining metabolic 
flexibility in a healthy skeletal muscle. These molecules have recently emerged as 
potential drug targets to combat diabetes.  
One strategy to activate the AMPK pathway is via altering the expression 
of AMP-metabolizing enzymes, such as 5’-nucleotidases [NT5C]. The role of cytosolic 
5´-nucleotidases was determined in metabolic responses linked to the development of 
insulin resistance in obesity and type 2 diabetes (Study I). NT5C1A and NT5C2 gene 
silencing led to increase in the AMP/ATP ratio, increase in phosphorylation of AMPK 
and ACC, and an increase in palmitate oxidation and glucose transport in mouse and 
human skeletal muscle.  
Another strategy to activate the AMPK system would be to lower the 
threshold of AMPK activation by rendering AMPK more sensitive to its activators. 
This strategy has been undertaken in this thesis by pre-treating skeletal muscle with 
methotrexate [MTX] and targeting 5-Amino-4-imidazolecarboxamide Ribonucleotide 
Transformylase [ATIC] (Study II). MTX is an inhibitor of ATIC, an enzyme involved 
in de-novo nucleotide biosynthesis. ATIC imposes a metabolic block leading to 
intracellular ZMP accumulation, lowering the threshold for AMPK activation. 
Increased glucocorticoid action leads to reduced whole body insulin 
action and may predispose to type 2 diabetes. Local conversion of cortisone to active 
cortisol by the enzyme 11β-hydroxysteroid dehydrogenase [11β-HSD1] in target 
tissues may regulate tissue specific roles of glucocortioids in pathophysiological states. 
Chronic high dose exposure to cortisone or cortisol reduced glucose metabolism and 
enhanced lipid metabolism, via induction of pyruvate dehydrogenase kinase 4 [PDK4] 
expression in myotubes. siRNA-mediated reduction or pharmacological inhibition of 
11β-HSD1 prevented the effects of cortisone but not cortisol, on metabolic responses 
(Study III).  
Type 2 diabetes mellitus is associated with abnormal substrate 
metabolism, raising the possibility that alterations in the expression of mitochondrial 
enzymes controlling lipid uptake and metabolism may be altered (Study IV). Evidence 
that expression of key enzymes regulating mitochondrial function in skeletal muscle is 
altered in type 2 diabetes mellitus [T2DM] patients is provided. 
In summary, activation of AMPK can play a central role in overcoming 
impairments in skeletal muscle glucose and lipid metabolism and this can be achieved 
by perturbing the enzymes involved in nucleotide metabolism such as 5’-nucleotidases 
and ATIC. Alterations in molecular regulators of substrate metabolism such as PDK4, 
reflect pathogenic condition and could be targeted to restore skeletal muscle energy 
homeostasis.     
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1 INTRODUCTION AND BACKGROUND 
1.1 ENERGY HOMEOSTASIS 
Energy homeostasis is critical for the survival of organisms. The control of the 
metabolic fuel supply and energy homeostasis are central factors in the rising 
magnitude of obesity, type 2 diabetes and metabolic syndrome. The human body needs 
to be well adapted to cope with major challenges in the supply and demand of energy. 
This adaptability requires the body to be capable of utilizing carbohydrate and lipid 
fuels and to shift from its dependency on these fuel sources. The switch between and 
lipids and glucose during the fasted and fed state has been described as ‘metabolically 
flexible’ (Kelley, 2005). 
 
The primary fuels in humans are carbohydrates (glucose), lipids (fatty acids) and to a 
lesser extent amino acids, which contribute to whole body energy homeostasis. A 
western diet consists of approximately 50% of energy contributed by carbohydrates, 
33% by fat and 17% by amino acids. However just after an overnight fast, there is a 
dramatic change in the fuel utilization, such that the carbohydrates account for only 
12% of the energy contribution, while 70% of the energy is contributed by fats and 
18% by amino acids (Randle, 1995). This ability to switch between utilization of lipids 
and glucose as oxidative fuel in response to fasting or feeding respectively is a key 
feature of the skeletal muscle (Figure 1). 
 
The studies described in this thesis are designed to investigate the molecular 
mechanisms integrating glucose and lipid metabolism and maintaining energy 





















Figure 1: Schematic representation of metabolic flexibility in opposite states of 
metabolic health: At rest, a fasted healthy muscle relies primarily on fatty acid oxidation 
(FA) for energy, which is associated with a lower Respiratory Quotient (RQ) value (∼0.7). 
After a meal, a healthy muscle uses glucose (G) for energy, resulting in an increased RQ 
value, close to 1. This capability is impaired in a diabetic skeletal muscle rendering it 
metabolically inflexible. Figure adapted from Osler M.E and Zierath J.R. Endocrinology. 
2008 Mar; 149(3):935-41    
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1.2 TYPE 2 DIABETES 
Type 2 diabetes mellitus is a growing problem across the world. An estimated 246 
million people worldwide have type 2 diabetes and approximately 366 million people 
are estimated  to be affected by type 2 diabetes by the year 2030 (Wild et al., 2004). 
Type 2 diabetes mellitus, also known as adult-onset diabetes, maturity-onset diabetes, 
or non-insulin-dependent diabetes mellitus is caused due to a combination of defective 
insulin secretion and insulin resistance, or reduced insulin sensitivity. Insulin resistance 
exists whenever a normal concentration of insulin produces a less than normal 
biological response (Kahn, 1978). The state in which insulin resistant individuals are 
unable to secrete enough insulin to overcome the defect in insulin signaling, leads to 
development of type 2 diabetes. Several lines of evidence show that genetic 
susceptibility for type 2 diabetes could induce an early β-cell dysfunction, leading to 
progression of type 2 diabetes (Gloyn et al., 2009; Lyssenko et al., 2008). Although the 
underlying cause of diabetes is unknown, insulin resistance clearly plays a major role in 
the development and progression of the disease (Kadowaki et al., 1984; Taylor et al., 
1994). 
 
According to the current recommendation of the World Health Organization, a person 
is diagnosed as having diabetes mellitus if he or she is diagnosed with a fasting blood 
glucose ≥7.0 mmol/l or 2 hour plasma glucose ≥ 11.1 mmol/l after an oral glucose 
tolerance test. In addition to elevated blood glucose levels, type 2 diabetic patients are 
characterized by a decreased fat oxidative capacity and high levels of circulating free 
fatty acids (FFAs). The latter is known to correlate with insulin resistance, particularly 
in skeletal muscle, by reducing insulin-stimulated glucose uptake. Furthermore, type 2 
diabetes is associated with impaired “metabolic flexibility” (Figure 1), i.e. an impaired 
switch from fat to glucose oxidation in response to insulin (Kelley, 2005; Kelley et al., 
1999; Kelley et al., 2002). Thus, a reduced ability to oxidize lipids and/or metabolic 
inflexibility, are important components of skeletal muscle insulin resistance. 
Additionally, insulin resistance as well as a cluster of risk factors which often coexist, 
including high plasma triglycerides, low high-density lipoprotein cholesterol and 
essential hypertension, together increase the risk of cardiovascular disease. This 
condition has been termed the ‘metabolic syndrome’, and insulin resistance per se has 
been postulated as an underlying mechanism (Reaven, 2005a, b). The cause of 
derangements in skeletal muscle of type 2 diabetic patients remains to be elucidated. 
Given the current world wide increase in type 2 diabetes prevalence, investigations into 
the underlying mechanisms of this disease continue to be important.  
 
1.3 SKELETAL MUSCLE AND METABOLISM 
Skeletal muscle is one of the major consumers of circulating fuels in the body partly 
because of its large mass as compared to other tissues, and partly due to higher 
metabolic demands during strenuous activities. Skeletal muscle is a major site of 
substrate metabolism and responsible for insulin- and exercise-mediated glucose 
disposal. Skeletal muscle accounts for ~75% of insulin-mediated glucose uptake 
(DeFronzo et al., 1985). Glucose is a major fuel for skeletal muscle and an impairment 
in its transport across the plasma membrane and subsequent utilization is one of the 
major pathogenic features of type 2 diabetes (DeFronzo et al., 1992).    
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1.4 INSULIN SIGNALING AND ACTION IN SKELETAL MUSCLE 
In the early 1920s, insulin was identified as the major hypoglycemic hormone having 
the ability to restore normal blood glucose levels in pancreatectomized animals and 
insulin-deficient humans (Banting et al., 1922). The physiological action of insulin on 
glucose metabolism primarily takes place in skeletal muscle, liver and adipose tissue. 
The effects of insulin on skeletal muscle metabolism are mediated by binding of insulin 
to high affinity, cell surface tyrosine kinase receptors called insulin receptors. Insulin, 
when bound to these receptors activates the intrinsic tyrosine kinase activity of the 
receptor’s intracellular domain leading to autophosphorylation of the insulin receptor 
internal kinase domain (Kasuga et al., 1982a; Kasuga et al., 1982b) and 
phosphorylation of Insulin Receptor Substrates [IRS]. Phosphorylated IRS proteins 
recruit and activate intracellular effector molecules containing Src Homology 2 
domains including regulatory domain of PtdIns (3, 4, 5) [PI] 3-kinase (Backer et al., 
1992; Myers et al., 1992). Activation of PI3-kinase leads to activation of several 
downstream kinases, including Akt/PKB (Alessi et al., 1997), and subsequently the 
rabGAP proteins TBC1D1/TBC1D4 propagating specific signals that elicit biological 
effects on glucose uptake in skeletal muscle (Sano et al., 2003; Taniguchi et al., 2006) 























1.4.1 Insulin action on skeletal muscle glucose metabolism 
Glucose transport across the plasma membrane is achieved by family of proteins 
comprising 13 members called “glucose transporter proteins” or “GLUTs” (Joost et al., 
2002). Skeletal muscle expresses the glucose transporters GLUT1, GLUT4 and GLUT 
12, with GLUT4 playing a role as the predominant isoform (Birnbaum, 1989; James et 
Figure 2: Schematic outline of insulin-mediated GLUT4 translocation to the plasma 
membrane in skeletal muscle.  
 4 
al., 1988). GLUT4 is responsible for insulin- and contraction-mediated glucose disposal 
in skeletal muscle (Douen et al., 1990), while GLUT 12 has been recently implicated in 
insulin-stimulated glucose transport (Stuart et al., 2009). GLUT1 expression is 
relatively lower in skeletal muscle compared to GLUT4 and is localized primarily in 
the plasma membrane and is thus thought to be participating in basal glucose transport 
(Gulve et al., 1994; Marshall and Mueckler, 1994). 
 
Once glucose is transported through the sarcolemma into the cytosol, it is 
phosphorylated to glucose-6-phosphate and after which the fate of the glucose molecule 
inside the cell is diverse. Glucose-6-phosphate is catabolized through glycolysis, the 
hexose monophosphate shunt and mitochondrial oxidation yielding high energy stores 
such as ATP and NADPH. Glucose can also be stored in the form of glycogen in 
skeletal muscle, enter the pentose phosphate pathway or be converted into triglycerides. 
 
Glucose has different metabolic fate depending on whether the conditions are aerobic 
or anaerobic. Under anaerobic conditions, pyruvate, the end product of glycolysis, is 
converted into lactate by lactate dehydrogenase enzyme (McLane and Holloszy, 1979). 
Under aerobic conditions, glucose through glycolysis is converted to pyruvate which is 
then converted into Acetyl CoA by the pyruvate dehydrogenase complex [PDC] in the 
mitochondrial matrix, and subsequently undergoes further oxidation through the Tri 
Carboxylic Acid cycle [TCA] to form carbon dioxide and water as end products.       
 
1.4.2 Insulin action on skeletal muscle lipid metabolism 
The concentrations of circulating ketone bodies are low in the fed or insulin-stimulated 
state and high during the fasted state. Ketone bodies are the end products of fatty acid 
oxidation in the liver. These observations led to the discovery of role of malonyl CoA 
in regulating fatty acid oxidation by McGarry and co-workers in 1977. The role of 
malonyl coA is well-appreciated as being an integrating point between glucose and 
lipid metabolism. In the fed state, glucose is converted to acetyl CoA by glycolysis and 
action of the PDC. Mitochondrial acetyl CoA can be exported to the cytosol by 
converting into citrate and transported by tricarboxylate transporter, then cleaved by 
ATP citrate lyase, to liberate the acetyl CoA in the cytosol. Cytosolic acetyl CoA is the 
starting point for de novo synthesis of fatty acids. The first step in this process is 
formation of malonyl CoA by action of acetyl CoA carboxylase enzyme [ACC]. 
Malonyl CoA was discovered to be potent inhibitor of fatty acid oxidation and 
ketogenesis (McGarry et al., 1977; Ruderman et al., 1999). Malonyl CoA allosterically 
inhibits carnitine-palmitoyl transferase-1 [CPT1], responsible for the transport of the 
fatty acids into the mitochondria for fatty acid oxidation. Thus, in the fed or insulin-
stimulated state, malonyl CoA formation inhibits fatty acid oxidation and ketogenesis. 
In fact, the skeletal muscle isoform of CPT1 is 10-100 times more sensitive to 
inhibition by malonyl CoA than the liver isoform (Jackson et al., 1999; Zammit, 1999). 
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1.5 PHARMACOLOGICAL MANIPULATON OF MUSCLE LIPID 
ACCUMULATION 
 
Obesity is an important risk factor for the development of type 2 diabetes. Weight gain 
(or loss) is closely correlated with decreasing (or increasing) insulin sensitivity 
(Friedman et al., 1992). Impairments in fatty acid metabolism are recognized as major 
components of pathogenesis of obesity and type 2 diabetes. Accumulation of 
intramyocellular triglycerides is implicated in the development of skeletal muscle 
insulin resistance (Krssak et al., 1999). The role of intracellular triglycerides in the 
development of skeletal muscle insulin resistance clearly raises the immediate need for 
approaches to regulate muscle lipid supply. A critical player in promoting skeletal 
muscle fatty acid oxidation and thus regulating intramuscular triglycerides is AMP-
activated protein kinase [AMPK]. 
 
1.6 AMPK AS AN EMERGING ANTI-DIABETIC DRUG TARGET        
AMPK has emerged as a major energy sensor and it is recognized as a key player in 
regulating cellular energy balance as it acts as a master regulator of cellular metabolic 
homeostasis (Hardie, 2007a; Long and Zierath, 2006; Towler and Hardie, 2007) 
(Figure 3). AMPK is a phylogenetically conserved enzyme present from unicellular 
eukaryotes to mammals (Hardie, 2007b). The role of AMPK as a metabolic fuel gauge 
and master regulator of homeostasis has placed it at the center stage in studies of 
mechanism contributing to the development of diabetes, obesity and metabolic 
syndrome. 
 
1.6.1 AMPK- structure and function 
AMPK is a heterotrimeric enzyme complex composed of a catalytic α-subunit and 
regulatory β and γ subunits. Each subunit is encoded by multiple genes. The α-subunit 
and the β subunit exist as two isoforms (α1, α2 and β1, β2) and the γ subunit exists as 
three isoforms (γ1, γ2 and γ3), rendering it possible to form 12 different heterotrimeric 
combinations. The catalytic α-subunit contains a kinase domain and the site T172 in 
this domain should be phosphorylated to render the kinase active (Hawley et al., 1996). 
The β-subunit acts as a core of the heterotrimeric structure and serves as a bridge 
interacting between the α-subunit and the γ-subunit. The γ-subunit contains two pairs of 
Bateman domains (cystathionine β-synthase), that bind an AMP molecule (Bateman, 
1997). The γ-subunit is a functional component of the AMPK heterotrimer rendering it 
responsive to AMP binding at the Bateman domain. The binding of the AMP molecule 
at the Bateman domain of the γ-subunit allosterically activates AMPK and also makes 
it a better substrate for upstream kinases and poorer substrate for phosphatases (Hawley 
et al., 2005; Hurley et al., 2005; Shaw et al., 2004). The AMPK system is essentially 
activated through sensing the disturbances in the intracellular abundance of AMP to 
that of ATP, thus sensing the intracellular nucleotide status. The physiological 
activation of AMPK in skeletal muscle occurs during conditions of increased binding 
of AMP and decreased binding of ATP to the γ-subunit. LKB1 has been recognized as 
an important upstream AMPK kinase regulating AMPK activity (Scott et al., 2002; 
 6 
Woods et al., 2003). Another upstream kinase, Ca2+/ Calmodulin dependent protein 
kinase has been identified as an important AMPK Kinase regulating its activity through 
intracellular calcium sensing (Hawley et al., 2005; Woods et al., 2005). Metabolic 
stressors, such as deprivation of glucose, hypoxia, and muscle contraction increase the 
intracellular concentration of AMP relative to ATP and activate the AMPK pathway. 
Once activated, AMPK switches on the catabolic pathways that generate ATP, while 








1.6.2 AMPK- Impact on lipid metabolism 
AMPK has been proposed as a drug target for the treatment of type 2 diabetes and 
obesity because of its effect on lipid metabolism (Moller, 2001; Zhang et al., 2009). 
When activated, AMPK in turn phosphorylates its immediate downstream target ACCβ 
rendering it inactive (Winder and Hardie, 1996). As ACC catalyses the formation of 
malonyl CoA, which inhibits CPT1, a decrease in ACC activity decreases the 
intracellular malonyl CoA concentration, thus releasing the inhibitory loop on CPT1 
and allowing the influx of long chain fatty acids into the mitochondria for beta 
oxidation. Another mechanism through which AMPK is thought to impact lipid 
metabolism in skeletal muscle is by directly acting on the enzyme malonyl CoA 
decarboxylase [MCD]. MCD is an enzyme involved in malonyl CoA degradation and 
its activity is increased following AMPK activation. This increased malonyl CoA 
clearance in skeletal muscle, releases the inhibition on CPT1 activity, leads to increased 
fatty acid influx in the mitochondria, and increases mitochondrial beta oxidation (Alam 
and Saggerson, 1998) (Figure 4). Treatment of rat skeletal muscle with an AMPK 
activator, AICAR, increases MCD activity and decreases ACC activity (Saha et al., 
2000).   
 
Figure 3: Multiple effects of AMPK activation on skeletal muscle metabolism. Once 
activated, AMPK switches on the catabolic pathways that generate ATP, while switches off 
the pathways that consume ATPs. 


























1.6.3 AMPK- Impact on glucose metabolism 
The rate of glucose transport in skeletal muscle can be increased by either insulin 
stimulation or muscle contraction (i.e. exercise) (Chibalin et al., 2000; Holloszy and 
Hansen, 1996; Kennedy et al., 1999; Thorell et al., 1999). AMPK plays a critical role in 
glucose metabolism. Activation of AMPK increases skeletal muscle glucose uptake via 
increased GLUT4 translocation (Kurth-Kraczek et al., 1999) (Figure 4). This effect of 
AMPK is independent of pathways regulating insulin-mediated GLUT4 translocation, 
since the effect is not blocked by PI3 kinase inhibitors, and effects of insulin and 
AMPK on glucose uptake are additive (Hayashi et al., 1998). In addition to playing a 
role in GLUT4 translocation to the plasma membrane, AMPK also exerts genomic 
effects by increasing the GLUT4 protein expression by enhancing the binding of the 
transcription factor myocyte enhancer factor 2 to the GLUT4 promoter region (Zheng 
et al., 2001).  
 
1.6.4 Development of AMPK activators 
Development of direct and indirect AMPK activators may hold promise as a new 
strategy to expand the armamentarium against type 2 diabetes (Fogarty and Hardie, 
2010; Hardie, 2011; Zhang et al., 2009). While direct activators bind to AMPK and 
trigger activation (Corton et al., 1995; Fogarty and Hardie, 2010; Guigas et al., 2009), 
indirect AMPK activators act mainly by increasing AMP/ATP ratio through different 
Figure 4: Schematic representation of the impact of AMPK activation on glucose and 
lipid metabolism.    
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mechanisms (Hawley et al., 2010), including modulation of intracellular nucleotide 
metabolism (Kulkarni et al., 2011).  
 
1.7 5’ NUCLEOTIDASES 
The 5’-nucleotidases are a family of enzymes that catalyze the dephosphorylation of 
nucleoside monophosphates and regulate cellular nucleoside and nucleotide levels 
(Bianchi and Spychala, 2003). The 5’-nucleotidase was first studied in vitro using a 
semi-purified enzymes extracted from rat and guinea pig skeletal muscle (Cozzani et 
al., 1969). There are various biochemical pathways that govern purine and pyrimidine 
nucleotide metabolism. These pathways maintain the levels of purine and pyrimidine 
nucleotide triphosphates vital to support various cellular processes. 5’-nucleotidases 
catabolize nucleoside monophosphates and change their abundance. Therefore they are 
components of cellular energy homeostasis. Besides maintaining balanced ribo and 
deoxyribonucleotide pools, nucleotidase activities are likely to regulate the activation of 
nucleoside analogues, a class of anti-cancer and anti-viral agents that rely on the 
nucleoside kinases for phosphorylation to convert to their phosphorylated active forms 
(Hunsucker et al., 2005). Early studies on 5’-nucleotidases have revealed a membrane 
bound ecto-enzyme and soluble form cytosolic enzymes. In humans, seven 5’-
nucleotidases have been isolated and characterized that vary in subcellular localization. 
Out of the seven known 5’-nucleotidases, five are of the soluble form and they are 
localized to cytosol, one is localized to the mitochondrial matrix (NT5M) and one is 
bound to the extracellular portion of the plasma membrane (the ecto 5’-nucleotidase or 
E5’N)  (Hunsucker et al., 2005). These enzymes have similar functions in that they 
hydrolyze 5’ nucleoside monophosphates, but they differ in their specificity towards 
their substrate. Some of these enzymes are ubiquitously distributed and some are tissue-
specific. Differences in subcellular localization, specificity towards their substrate and 
tissue specific distribution allow regulation of nucleotide pools to meet the energy 
balance and cellular homeostasis. This thesis will focus on two of the soluble 5’-
















Figure 5: The two enzymes studied in this thesis NT5C1A and NT5C2 have overlapping 
substrate specificities. NT5C1A is primarily AMP preferring enzyme while NT5C2 is 
primarily IMP preferring with overlapping specificity towards AMP. 5’-nucleotidases 
enzymes act on nucleoside mono-phosphates to produce nucleoside and inorganic 
phosphate. 
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NT5C1A was first described as an AMP preferring enzyme partially purified from 
pigeon ventricle (Gibson and Drummond, 1972) and was later purified from rabbit, rat, 
pigeon and dog heart (Darvish and Metting, 1993; Newby, 1988; Truong et al., 1988). 
In human tissues, NT5C1A mRNA expression is highest in skeletal muscle and is also 
present in heart, brain, pancreas, kidney, testis and uterus (Hunsucker et al., 2001). 
NT5C1A is closely related to NT5C1B, but these enzymes have little homology to 
other intracellular nucleotidases (Sala-Newby and Newby, 2001). While NT5C1A has a 
broad range of nucleotides and deoxynucleotides as substrates, the enzyme has a 
preference for AMP and pyrimidine deoxyribonucleotides (Garvey et al., 1998; 
Hunsucker et al., 2001). 
 
NT5C2 mRNA is ubiquitously expressed in human tissues, with the highest expression 
in pancreas, skeletal muscle and heart muscle (Allegrini et al., 1997; Rampazzo et al., 
1999). Cytosolic NT5C2 was first described as a nucleotidase partially purified from 
chicken liver that preferentially hydrolyzes 5’-IMP, 5’ GMP, 5’-dGMP and XMP (Itoh 
et al., 1967). NT5C2 not only hydrolyzes IMP, preventing conversion to GMP or AMP, 
but also hydrolyzes GMP to directly regulate guanine nucleotide pools. AMP is 
catabolized to IMP by AMP deaminase; subsequently, NT5C2 converts IMP to inosine. 
Thus, NT5C2 and AMP deaminase are important regulators of purine nucleotide pools.  
 
Another approach to activate the AMPK system would be to use a lower dose of an 
AMPK activator to amplify its ability to activate AMPK. This may decrease unwanted 
side effects caused by the unavailability of specific AMPK activators. For example, 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR], a commonly used 
activator of AMPK, is known to activate several other kinases (Lefebvre et al., 2001; 
Moopanar et al., 2006). 
 
1.8 ATIC 
The 5-aminoimidazole-4-carboxamide ribonucleotide formytransferase / inosine 
monophosphate [IMP] cyclohydrolase [ATIC], a bifunctional enzyme, which catalyzes 
the conversion of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside 5'-
monophosphate [ZMP, AICAR-monophosphate] to IMP in the final two steps of the de 
novo purine biosynthetic pathway (Allegra et al., 1985; Allegra et al., 1987; Baggott 
and Morgan, 2007). MTX and its analogue pemetrexed [PMX] primarily exert 
antineoplastic effects by disrupting DNA and RNA synthesis, but recent evidence 
associates these proteins with AMPK activation in cancer cells (Beckers et al., 2006; 
Racanelli et al., 2009; Rothbart et al., 2010). The molecular basis of MTX-mediated 
AMPK activation involves inhibition of ATIC. ZMP is also the biologically active form 
of the widely used cell-permeable AMPK activator AICAR (Corton et al., 1995; 
Guigas et al., 2009), which is phosphorylateded to ZMP by the intracellular adenosine 
kinase (Sabina et al., 1985; Samari and Seglen, 1998; Vincent et al., 1996). By 
preventing ZMP entry into the de novo biosynthetic pathway, MTX markedly 
potentiates AMPK activation in AICAR-treated cancer cells (Beckers et al., 2006). 
MTX can substantially increase the ZMP concentration and/or reduce adenylate energy 
charge in some, but not all, cell types (Allegra et al., 1987; Beckers et al., 2006; 
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Bokkerink et al., 1986a; Bokkerink et al., 1986b; Kaminskas, 1982; Kaminskas and 
Nussey, 1978; Racanelli et al., 2009), indicating it may also act as an indirect AMPK 
activator under certain conditions (Figure 10). 
 
1.9 ROLE OF GLUCOCORTICOIDS IN PATHOPHYSOLOGY OF 
METABOLIC SYNDROME 
Endogenous glucocorticoids are steroid hormones secreted from the adrenal cortex 
under the influence of the hypothalamic–pituitary–adrenal axis, which is an integral 
part of the stress response modulating a large number of physiological processes. 
Glucocorticoids bind to the glucocorticoid receptors, which are nuclear receptors and 
exert metabolic action by modulating the expression of target genes. Excess of 
circulating glucocorticoids have been linked to clinical manifestations overlapping with 
that of metabolic syndrome. These clinical characteristics include central obesity, 
hypertension, hyperlipidemia, insulin resistance and glucose intolerance (Figure 11). 
These symptoms are exacerbated in patients with Cushing’s syndrome, which is a result 
of glucocorticoid excess due to a pituitary adenoma. Patients administered with 
glucocorticoids to treat inflammatory diseases suffer adverse metabolic effects such as 
weight gain, hypertension and insulin resistance (Davis, 1986; Gallant and Kenny, 
1986). All these observations form the basis of a hypothesis to regulate pre-receptor 
glucocorticoid metabolism as a potential therapeutic strategy in treatment of metabolic 
syndrome. 
  
1.9.1 Glucocorticoid metabolism and action on skeletal muscle 
The intracellular glucocorticoid concentration is regulated by the 11β-hydroxysteroid 
dehydrogenase [11β-HSD1] enzyme, which converts inactive cortisone to active 
cortisol and thus modulates glucocorticoid action locally (Morton, 2010; Paterson et al., 
2004). 11β-HSD1 is expressed in variety of tissues such as liver, adipose, brain and 
kidney, while 11β-HSD2, an isozyme, responsible to convert cortisol to cortisone, is 
primarily expressed in kidneys and salivary glands (Walker and Stewart, 2003). 
Pathophysiological effects of glucocorticoids occur due to their actions on variety of 
tissues. Glucocorticoids enhance hepatic glucose production by inducing the enzyme 
phosphoenolpyruvate carboxykinase and thus positively affecting gluconeogenesis. 
Insulin secretion from pancreatic beta cells is inhibited by glucocorticoids. In skeletal 
muscle, excess glucocorticoids directly interfere with insulin signaling and decrease 
insulin-stimulated glucose uptake by preventing translocation of the glucose 
transporters from intracellular compartments to the plasma membrane (Morgan et al., 
2009; Nechushtan et al., 1987). In adipose tissue and liver, glucocorticoids act in 
conjugation with insulin to drive lipogenic enzymes and lipid uptake, causing hepatic 
lipid accumulation (Wang et al., 2004). These findings provide evidence to suggest that 
metabolic actions of glucocorticoids are exerted in multiple tissues and excess 
glucocorticoids contribute to the progression of metabolic syndrome. 
 
The enhanced rate of peripheral glucocorticoid clearance would help to curtail the 
metabolic complications mediated by excess local or circulating glucocorticoids. This 
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is supported by the finding that insulin sensitivity is increased and gluconeogenesis is 
decreased as a consequence of reduced intracellular glucocorticoids in mice with a 
targeted deletion of 11β-HSD (Kotelevtsev et al., 1999). Transgenic mice 
overexpressing 11β-HSD1 selectively in adipose tissue have increased visceral 
adiposity, insulin resistance, hyperlipidemia and hyperphagia (Masuzaki et al., 2001). 
Taken together these findings suggest that downregulation of 11β-HSD1 activity 
locally could act to limit the pathophysiological consequences of high glucocorticoid 
metabolism and curtailing associated conditions such as obesity and type 2 diabetes. 
 
1.10 MITOCHONDRIAL PROTEINS AS NOVEL CANDIDATES FOR 
MAINTAINING METABOLIC FLEXIBILITY? 
Skeletal muscle substrate metabolism plays a fundamental role in whole body nutrient 
utilization and homeostasis. A number of key mitochondrial enzymes determine the 
balance between glucose and fatty acid metabolism. Mitochondrial metabolism results 
from the concerted action of several biochemical reactions that are coordinately 
regulated. Some of the key enzymes include pyruvate dehydrogenase kinases [PDKs], 
CPT1b and MCD. Genotypic and physiological factors contribute to adversely affect 
mitochondrial metabolism, which perhaps also affects lipid metabolism governed by 
these mitochondrial genes. 
 
The pyruvate dehydrogenase complex [PDC] occupies a central position in 
mitochondrial metabolism. Since PDC represents a flux point for the entry of the 
carbohydrate derived fuel into the mitochondria for oxidation, it regulates overall 
substrate selection in skeletal muscle. The activity of the pyruvate dehydrogenase 
complex is negatively regulated by PDKs. There are four PDK isoforms (PDK1, 2, 3, 
4). In skeletal muscle the predominant form is PDK4 and to a lesser extent PDK2 
(Bowker-Kinley et al., 1998). Pyruvate dehydrogenase kinase phosphorylates PDC, 
leading to inhibition of the complex and reduced carbohydrate oxidation. Thus, PDC 
inhibition is recognized as a flux point at which fuel selection in skeletal muscle can be 
shifted towards fat oxidation (Sugden and Holness, 2006). Pyruvate dehydrogenase 
activity is decreased in response to fasting or high fat diet in human skeletal muscle 
(Putman et al., 1993). Exercise and contraction increase pyruvate dehydrogenase 
activity in human and rat skeletal muscle (Dohm et al., 1986a; Dohm et al., 1986b; 
Dyck et al., 1993). 
 
PDK4 is crucial for the regulation of pyruvate dehydrogenase activity and might be 
regulated at the level of transcription in response to exercise. PDK4 transcription and 
PDK4 mRNA are markedly increased in human skeletal muscle during exercise of 
acute high-intensity or prolonged low-intensity (Pilegaard and Neufer, 2004). Increased 
pyruvate dehydrogenase kinase activity in skeletal muscle suppresses glucose 
oxidation, and thus may cause or exacerbate hyperglycemia. Mice with a targeted 
deletion of PDK4 have lower blood glucose levels and slightly improved glucose 
tolerance compared to wild-type mice after an 18 week high fat diet (Jeoung and 
Harris, 2008), highlighting a role of PDK4 in the development of hyperglycemia. 
During a euglycemic hyperinsulinemic clamp, insulin exposure reduces PDK4 mRNA 
 12 
expression in normal glucose tolerant, but not in insulin resistant people, indicating 
elevations in PDK4 expression and activity may further increase plasma glucose level 
(Kim et al., 2006; Lee et al., 2004). 
 
Mitochondrial activity and function in skeletal muscle is a highly controlled process, 
under the influence of a variety of nuclear and mitochondrial factors that act as 
metabolic sensors, which adapt to perturbations in cellular nutrient and energy status. 
MCD and CPT1 play a pivotal role in fuel selection and drive increases in fatty acid 
oxidation. MCD and CPT1b (muscle isoform) coordinate fuel balance during exercise 
and states of metabolic disease. Exercise reduces skeletal muscle malonyl CoA 
(Roepstorff et al., 2005) and increases expression of MCD1 (Kuhl et al., 2006), which 
may contribute to the increase in lipid oxidation at the onset of exercise (Roepstorff et 
al., 2005). Increased levels of malonyl CoA have been reported in insulin resistant 
animal models (Assifi et al., 2005). However, MCD knockdown protects against the 
development of dietary-induced whole body insulin resistance in mice (Koves et al., 
2008) and enhances insulin-stimulated glucose uptake in human muscle cells (Bouzakri 
et al., 2008). CPT1b expression and function has been linked to the regulation of 
insulin sensitivity. Chemical inhibition of CPT1b with the pharmacological agent 
Etomoxir increases lipid deposition and exacerbates insulin resistance in rats fed a 
high-fat diet (Dobbins et al., 2001), while overexpression of CPT1b in rat hindlimb 
muscle by electrotransfer prevents the dietary-induced insulin-resistance on glucose 
uptake (Bruce et al., 2009). Whether MCD or CPT1b levels are altered or related to the 
metabolic phenotype in type 2 diabetes is unknown. 
 
This thesis aims to investigate new strategies to combat impairments in skeletal muscle 
glucose and lipid metabolism and restore the overall skeletal muscle energy 
homeostasis.  
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2 AIMS AND OBJECTIVES 
One of the key features of healthy skeletal muscle is the ability to switch between 
utilization of lipids and glucose as fuel in response to feeding or fasting respectively. 
This metabolic flexibility is impaired in skeletal muscle from insulin resistant and type 
2 diabetic patients. Molecules such as AMPK and PDK play crucial roles in 
maintaining metabolic flexibility in healthy skeletal muscle. The overall goal of this 
thesis work is to identify and validate novel molecules which are involved in 
maintaining the metabolic flexibility of the skeletal muscle. 
 
2.1 SPECIFIC GOALS 
2.1.1 Specific aims of the present investigation are as follows: 
 To determine whether cytosolic 5’-nucleotidases play a role in maintaining 
skeletal muscle energy metabolism. Could targeting 5´-nucleotidases be a 
potential strategy to activate AMPK pathway? 
 
 To determine whether modulation of the enzymes of nucleotide metabolism 
reduce the threshold for AMPK activation and potentiate AICAR-stimulated 
AMPK activity. 
 
 To determine whether reduction in 11β-HSD1 prevents cortisone- or cortisol-
mediated metabolism in skeletal muscle. What is the molecular link for the 
glucocorticoid-mediated shift in metabolism in skeletal muscle? 
 
 To determine whether alterations in skeletal muscle expression and/or 
regulation of mitochondrial proteins involved in fatty acid metabolism reflect 
metabolic dysfunction. Does increase in physical activity restore metabolic 
dysfunction and reflect normal mitochondrial fatty acid metabolism?  
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3 EXPERIMENTAL PROCEDURES 
3.1 MATERIALS AND METHODS 
3.1.1 Recruitment of subjects for lifestyle intervention 
This investigation included 112 individuals without severe physical or cardiovascular 
impairments aged 61 (57–64) years, with BMI of 29 (27.5–32.0) kg ⁄m2. Subjects were 
stratified based on normal glucose tolerance (n = 79) or type 2 diabetes mellitus (n = 
33). Of the total number of volunteers, a subgroup of male participants in each category 
(NGT n=23, T2DM n=17) underwent an exercise intervention. Subjects were directed 
to engage in Nordic walking with walking poles, 5 hours per week for 4 months. Self-
reported physical activity was assessed at the time of inclusion and after 4 months. 
Remaining volunteers maintained their habitual lifestyle.  Written informed consent 
was obtained from all participants. The study was approved by the Ethics Committee of 
Karolinska Institutet, Stockholm. 
 
3.1.2 Human Vastus Lateralis muscle biopsies 
Skeletal muscle biopsies were obtained (Study IV) from subjects in the morning, 
following an overnight fast. Local anesthesia (lidocaine hydrochloride, 5 mg/ml) was 
administered, and an incision (5 mm long/10 mm deep) was made in the skin and 
skeletal muscle fascia. A biopsy (20-100 mg) was obtained from vastus lateralis 
portion of thigh muscle using a conchotome tong. Biopsies were immediately frozen in 
liquid nitrogen until analysis. 
 
3.1.3 Human Rectus Abdominis muscle biopsies 
For Study I, III, IV muscle biopsies were obtained from subjects scheduled for 
abdominal surgery at Karolinska University Hospital, Stockholm, Sweden. Skeletal 
muscle biopsies (rectus abdominis) were obtained during scheduled abdominal surgery 
with informed consent from the donors. The subjects were 61±5 years (BMI 26 kg/m
2
), 
with no known metabolic disorder. The study was approved by the Ethics Committee 
of Karolinska Institutet, Stockholm 
 
 
3.1.4 Isolation of human skeletal muscle satellite cells 
Satellite cells were isolated from the rectus abdominis biopsies by trypsin and 
collagenase digestion and grown to myoblasts and differentiated to myotubes (Al-
Khalili et al., 2003; Al-Khalili et al., 2004). The biopsy material was collected in cold 
phosphate buffered saline (PBS) containing 1% penstrep (100 units/ml penicillin/ 100 
µg/ml streptomycin) and 1% fungizone Gibco BRL (Invitrogen, Stockholm, Sweden). 
The connective tissue was teased out by dissection while the muscle was finely diced 
and bundles of muscle fibers were isolated and then transferred to the trypsin-EDTA 
digestion solution Gibco, BRL (Invitrogen, Stockholm, Sweden).  The muscle fibers 
were incubated in trypsin digestion solution at 37ºC for 15-20 minutes with gentle 
agitation every 5 minutes. The tube was subjected to centrifugation 350 g for 10 
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minutes to pellet down the undigested tissue. The supernatant containing satellite cells 
was collected in a separate tube and mixed with the growth medium (Hams F10 with 
20% FBS, 1% penstrep, 1% fungizone) in 1:1 ratio. The remaining undigested muscle 
was then transferred to a fresh trypsin digestion solution and incubated at 37ºC for 
another 15 minutes, centrifuged and resultant supernatant was pooled with the 
previously collected supernatant. The pooled supernatant was then subjected to 
centrifugation at 2000 g for 10 minutes. The supernatant was discarded and the 
pelleted cells were resuspended in 5 ml of the growth media and incubated in a 
bacteriological non-coated culture dish to promote the adherence of non-myogenic 
cells for 30-40 minutes. After incubation, the media containing the isolated satellite 
cells was transferred to a new 25 cm
2
 culture flask. The culture flask media was 
changed every 2 days with fresh medium.   
 
Dulbecco’s modified Eagle’s medium (DMEM), Ham’s F-10 medium, fetal bovine 
serum, penicillin, streptomycin and fungizone were obtained from Gibco BRL 
(Invitrogen, Stockholm, Sweden). Unless specified, all reagents were purchased from 
Sigma. Radioactive reagents were purchased from Amersham. 
 
3.1.5 Human skeletal muscle cell culture 




 and cultivated in growth media 
(Ham’s F-10 media with 20% FBS, 1% penstrep, 1% fungizone) in tissue culture 
dishes. When cells were almost 80% confluent, they were subjected to the start of the 
differentiation program by supplementing them with a differentiation medium (DMEM 
1 g/L glucose media with 2% FBS, 1% penstrep and 1% fungizone). Upon initiating the 
differentiation program, the myoblasts fuse to form multinucleated myotubes that are 
visible by the third day of the differentiation. All the experiments were performed on 
fully differentiated myotubes around 5-6
th
 day of differentiation.    
 
3.1.6 Rat L6 muscle cell culture 
Rat L6 skeletal muscle cells were cultivated in alpha-MEM growth media containing 
10% FBS (Study II). Once the seeded cells reached 80% confluence, similar to human 
skeletal muscle cells, a differentiation program was initiated by supplementing the cells 
with alpha-MEM differentiation medium (2% FBS) instead of the alpha MEM growth 
medium. All the experiments were performed on the fully differentiated myotubes 
around 6
th
 day of differentiation. 
 
3.1.7 siRNA transfections 
3.1.7.1 Human skeletal muscle cells 
Myotubes cultured in 6-well plates were transfected using Lipofectamine 2000 reagent 
(Invitrogen) following manufacturer’s directions. Differentiation medium was changed 
to antibiotic-free growth medium on day 0 and 2 of the myotube differentiation 
protocol. On days 0 and 2, myotubes were transfected with individual siRNAs (1 
μg/ml) using Lipofectamine 2000 in serum-free DMEM. In Study Ι, pools of four 
siRNAs directed against human NT5C2 or a scrambled sequence were used. In Study 
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ΙΙΙ, 11β-HSD1 or PDK4-directed siRNAs were transfected into cells following four 
days of exposure to glucocorticoid hormones.  siRNA oligonucleotides for NT5C2 
(Study Ι) and 11β-HSD1 and PDK4 (Study ΙΙ) were purchased from Dharmacon 
(Chicago, IL). Myotubes were washed with PBS, and 2 ml of DMEM containing 2% 
fetal bovine serum was then added to each well.  
 
3.1.7.2 Rat L6 muscle cells 
Myotubes were cultured in 6-well plates and transfected with 100 nM pools of siRNAs 
(Dharmacon, Chicago, IL) against rat ATIC mRNA (Study ΙΙ) using calcium phosphate 
(CellPhect Transfection kit; GE Healthcare) on days 2 and 4 of differentiation. siRNA-
calcium phosphate precipitates were removed 16–18 h after the addition of siRNA by 
washing with PBS and adding 2 ml αMEM supplemented with 2% FBS. Experiments 
were performed 48–72 h after the last transfection. A scrambled siRNA was used as a 
control in all experiments. On day 6 of the differentiation protocol, the myotubes were 
serum starved for 4 h before the start of the experiment.  
 
3.1.8 Gene expression measurement 
Gene expression (Study I, III, and IV) was measured by real-time polymerase chain 
reaction (RT-PCR) using TaqMan technology. In the TaqMan chemistry, a fluorogenic 
probe is used to add specificity to the reaction. The probe has a reporter fluorescent dye 
at the 5’ end and a quencher dye at the 3’ end, and anneals downstream of the primer 
on the target sequence. When the probe is intact, the quencher dye greatly reduces the 
reporter dye. During the PCR reaction the Taq polymerase cleaves the probe and the 
reporter dye no longer is inhibited by the quencher dye, giving a signal responding to 
the amplification of the target sequence.  
 
3.1.9 Metabolic assays 
3.1.9.1 Glucose uptake 
Radio labeled 2-deoxy-D-glucose was utilized to determine the glucose uptake in the 
cultured human myotubes (Study I, III). 2-deoxy-D-glucose is a glucose analogue that 
is taken up by the cell and phosphorylated by the enzyme hexokinase to 2-deoxy-D-
glucose-6-phosphate which cannot be further metabolized. Hence the phosphorylated 
form of 2-deoxy-D-glucose is trapped inside the cell and can be measured by 
scintillation liquid counting and an estimate of glucose accumulated inside the cell can 
be determined. Myotubes were grown and differentiated in six-well plates and serum 
starved overnight. Cells were pre-incubated in the absence or presence of insulin (120 
nM) or AICAR (1 mM) for 1 hour in glucose- and serum-free DMEM. Thereafter, 
myotubes were incubated in glucose-free DMEM containing [
1,2-3
H]-2-deoxy-D-
glucose glucose (0.33 μCi/mL) and 10 μM unlabeled 2-deoxy-D-glucose and glucose 
uptake (Al-Khalili et al., 2003; Al-Khalili et al., 2004). Experiments were performed in 
triplicate and results were normalized by protein concentration determined by the BCA 
method (BCA Protein Assay Kit, Thermo Scientific, Rockford, IL). The radioactivity in 
20 µl of incubation media with known concentration was measured; results are 
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expressed in terms of the amount of glucose taken up by the cells per minute per 
milligram protein or by representing as fold over basal. 
 
3.1.9.2 Glucose oxidation 
Myotubes were incubated for 4 hours in 1 ml serum-free DMEM supplemented with 
0.1% fatty acid free BSA, D-[U-
14
C] glucose (1 µCi/ml; final specific activity, 0.18 
µCi/µmol, Amersham), 120 nM insulin, 1 mM AICAR to the respective wells. 
Thereafter, 150 μl solvable (aqueous based tissue solubilizer, Perkin Elmer Life 
Science and Analytical Science, Boston, MA) was dispensed into a center-well 
positioned in each dish and 150 μl of 35% perchloric acid [PCA] was added to the 
medium. Myotubes were incubated for an additional hour, after which the center well 
was removed subjected to scintillation analysis (Study I). 
 
3.1.9.3 Glucose incorporation into glycogen 
Glycogen synthesis was determined by assessing the conversion of labeled glucose into 
glycogen (Study I, III) (Al-Khalili et al., 2003; Al-Khalili et al., 2004). Skeletal muscle 
myotubes were grown on a six-well plates and serum starved for 12-16 hours following 
five days of differentiation. Myotubes were incubated in DMEM containing 5 mM 
glucose and D-[U-
14
C] glucose (1 µCi/ml; final specific activity, 0.18 µCi/µmol). 
Myotubes were incubated in the absence or presence of insulin (120 nM) for 90 
minutes at 37
o
C. Experiments were performed in triplicate. The reaction was 
terminated by placing the six-well plates on ice; myotubes were washed three times 
with ice-cold PBS and lysed in 1 ml of 0.03% sodium dodecyl sulfate [SDS]. After an 
overnight freeze thaw cycle, 0.85ml of lysate was transferred to 10 ml tubes and 100 µl 
of carrier glycogen (20 mg/ml) was added and samples were heated to 100ºC for 1-2 
hours. Three ml of 98% ethanol was added to the samples and incubated at -20
o
C 
overnight to precipitate the glycogen.  The samples were subjected to centrifugation at 
1700 g for 35 minutes. The glycogen pellet was washed once with 70% ethanol and 
resuspended in 400 µl of distilled water, which was used for liquid scintillation 
counting to measure the radioactivity (WinSpectral 1414 Liquid Scintillation Counter; 
Wallac/PerkinElmer, Waltham, MA, USA). The remaining lysate from the experiment 
was used to determine protein concentration by the BCA method which was used for 
normalization. 
 
3.1.9.4 Palmitate oxidation method I 
Lipid oxidation was assessed by exposing myotubes to [
3
H] palmitic acid and 
measuring the tritiated water produced (Study I) (Rune et al., 2009). Myotubes were 
cultured in six well plates and serum starved overnight. Cells were washed once with 
PBS and exposed to 1 ml of DMEM (1 g glucose/L), supplemented with 0.2% fatty 
acid free BSA and 0.5 µCi palmitic acid [9-10(n)-
3
H], and incubated in the absence or 
presence of 1 mM AICAR for 4 hours. To adsorb non-metabolized palmitate, 0.2 ml of 
cell supernatant was mixed with 0.8 ml charcoal slurry (0.1 g charcoal powder in 1 ml 
0.02 M tris-HCl buffer, pH 7.5) and shaken (30 minutes). Samples were subjected to 
centrifugation for 15 minutes at 13,000 rpm, after which 0.2 ml of supernatant with 
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tritium bound water was withdrawn and radioactivity was measured by liquid 
scintillation counting (WinSpectral 1414 Liquid Scintillation Counter; Wallac, Turku, 
Finland). Each experiment was performed in triplicate.  
 
3.1.9.5 Palmitate oxidation method II 
Myoblasts were grown in 25 cm
2
 cell culture flasks and differentiated to myotubes at 
>80% confluence (Study III). Before starting the experiment, a 2 mm hole was made in 
the lid of each flask and two sheets of 24 mm Whatman filter (Cat No 108340-24, 
VWR International AB, Sweden) were covered with a gauze bandage circle, prepared 
by cutting gauze into the same shape as the Whatman filter. The filter and gauze 
sandwich was then pressed into the inside of the culture flask lid, and the lid was sealed 
with Parafilm. Overnight serum starved myotubes (eight days after differentiation) 
were treated for 180 min with 0.4 μCi of [1-14C] palmitate in 2 ml serum-free DMEM 
at 37ºC, in 5% CO2–95% O2 with the filterlid tightly closed and sealed with Parafilm 
(Nordic EM Supplies, Espoo, Finland). Thereafter, 200 μl of Solvable reagent 
(benzethonium hydroxide, Packard, PerkinElmer Sweden) was added drop-wise 
through the hole of the lid to soak the filter, followed by 250 μl of 35% perchloric acid. 
The lids were then sealed with Parafilm to prevent escape of gas from the flasks 
through the hole. Flasks were gently agitated for 1 h at room temperature. The filter 
compass was removed to a scintillation tube and 10 mL of scintillation liquid and 200 
μl of icecold methanol were added. The level of trapped 14CO2 in the filter was 
determined in a liquid scintillation counter. 
 
3.1.9.6 Media lactate concentration 
Myotubes were incubated overnight in the presence or absence of AICAR (1 mM) in 
serum-free DMEM. Media (100 µl) was collected in duplicate and lactate concentration 
was determined (Bouzakri et al., 2008) using a commercially available kit (Study I) (A-
108; Biochemical Research Service Center, University of Buffalo, Buffalo, NY). 
 
3.1.10 Extraction of nucleotides 
Differentiated skeletal muscle myotubes from 10 cm dishes were washed three times 
with ice-cold PBS and scraped in 300 μl of ice cold 5% perchloric acid. Tibialis 
anterior muscle (~50 mg) was powdered in liquid nitrogen and then homogenized in 
0.2 ml of 5% (by volume) perchloric acid. Samples were subjected to centrifugation 
(14,000 rpm for 3 minutes at 4ºC) to remove insoluble material. A solution containing 
an equal volume of 1, 1 tri-n-octylamine and 1, 1, 2,-trichlorotrifluoro ethane (total 
volume 220 µl) was added to the supernatant and the sample was rigorously vortexed. 
After centrifugation, the upper aqueous layer was removed and extracted a second time 
with a further addition of 220 μl of the same organic solvent mixture as identified 
above (Study I). An aliquot (20 μl) of the final aqueous phase was analyzed by 
capillary electrophoresis with on-column isotachophoretic pre-concentration, using a 
leading buffer consisting of 50 mM sodium phosphate and 50 mM NaCl (pH 5.2), and 
a tailing buffer containing 100 mM MES/Tris pH 5.2. To each buffer, 0.2% 
hydroxyethyl-cellulose was added to decrease the electro-osmotic flow. Nucleotide 
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peaks were detected by UV absorbance at 260 nM (ref. 400 nM), and integrated using 
System Gold Software (Beckman). Nucleotide ratios were calculated from peak areas 
after correction for retention times (Sakamoto et al., 2005).  
 
3.1.11 Determination of protein concentration  
3.1.11.1 Protein concentration in cell culture 
To determine the total protein concentration, myotubes were grown and differentiated 
in six welled plates or 100 mm dishes and cells were lysed in 50 µl/well or 300 µl/ dish 
homogenization buffer. The homogenates were solubilized by vortexing and subjected 
to centrifugation at 4ºC at 12000 g for 10 minutes. The supernatant was collected and 
total protein was determined by BCA method using a commercially available kit 
(Pierce, Rockford, IL). The supernatant was stored at -80ºC for preparation of samples 
for immunoblot analysis.  
 
3.1.11.2 Protein concentration in skeletal muscle biopsy 
Frozen muscle biopsies were homogenized in ice cold buffer (10% glycerol, 5 mM 
sodium pyrosulfate, 13.7 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 20 mM Tris (pH 7.8), 
1% Triton X100, 10 mM NaF, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 
µg/ml aprotinin, 1 µg/ml leupeptin, 0.5 mM sodium vandanate, 1 mM benzamidine, 1 
µM microcystin) for 20 seconds using a motor-driven pestle. Homogenates were 
rotated end-over-end for 1 hour at 4
o
C and then subjected to centrifugation (12,000 g 
for 10 minutes at 4
o
C). The supernatant was collected and total protein was determined 
by BCA method using a commercially available kit (Pierce, Rockford, IL). The 
supernatant was stored at -80ºC for preparation of samples for immunoblot analysis. 
 
3.1.12 Immuno blot analysis (Western blot) 
Protein expression or phosphorylation in either cultured myotubes or muscle biopsies 
was accessed by western blot analysis. Equal concentration of the homogenized lysate 
was mixed with 4X Laemmli buffer containing β-mercaptoethanol and heated at 56ºC 
for 30 minutes. Proteins were subjected to SDS-PAGE and separated on a 4-12% 
precast gradient agarose gel (Criterion, Bio-Rad). The separated proteins were then 
transferred to polyvinylidenediflouride (PVDF) membrane (Immobilon-P, Millipore, 
Bedford, MA, USA). After the protein transfer, the membranes were incubated in 7.5% 
low fat milk in Tris-buffered Saline and Tween 20 [TBST] for 1-2 hours at room 
temperature. The blocked membranes were then washed in TBST to remove the milk 
and then incubated in respective primary antibody diluted in TBST and 0.01% sodium 
azide overnight at 4ºC (16 hours). The incubated membranes were then washed in 
TBST for 4 times 10-15 minutes each and incubated in appropriate horse radish 
peroxidase conjugated secondary antibody at room temperature for 1 hour. After 
washing the membrane to remove the secondary antibody for 3 times 10-15 minutes 
each, the proteins were visualized by enhanced chemiluminescence using ECL reagent 
(GE Healthcare, UK) and quantified by densitometry. Results were expressed as 
arbitrary units normalized to loading controls.   
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3.1.12.1 Membrane stripping  
When required and specified, PVDF membranes were stripped in buffer (62.5 mM 
Tris-HCl pH 6.8, 10 mM β-mercaptoethanol and 2% (w/v) SDS) for 40 minutes at 56ºC 
to remove the primary and secondary antibodies followed by washing in TBST and 
further incubation in 7.5% low fat milk dissolved in TBST for 2 hours. After a brief 
wash to remove the milk particles, the membrane was incubated in the primary 
antibody of interest overnight at 4ºC.   
 
3.1.13 Animal models 
The C57BL/6 mice were used in Study I and AMPKγ3 KO mice and their wild-type 
littermates were investigated in Study II. Animals were maintained on a 12 hour light-
dark cycle and were allowed to have a free access to standard rodent chow. Animals 
were fasted for 4 hours before the experiments. All the experiments were approved by 
the Regional Animal Ethical Committee Stockholm, Sweden. The C57BL/6 mice were 
purchased from Charles River Laboratories (Germany) and the AMPKγ3 KO and their 
respective wild-type littermates were bred in-house. The generation of the AMPKγ3 
KO mice has been previously described (Barnes et al., 2004).  
 
3.1.14 Isolated skeletal muscle incubations    
Mice were anesthetized via an intraperitoneal injection 2.5% Avertin (2, 2, 2-tribromo 
ethanol 99% and Tertiary amyl alcohol) (0.02 ml/g of body weight) and extensor 
digitorum longus (EDL) and Soleus muscle were carefully dissected and removed 
further analysis. Krebs-Henseleit buffer [KHB] supplemented with 5 mM glucose, 15 
mM mannitol, 5 mM HEPES and 0.1% BSA (RIA grade) was pre-gassed (95% 
oxygen, 5% CO2) and used as a basal incubation buffer. Immediately after dissection, 
the muscles were allowed to recover for 20 minutes in basal incubation buffer.  The 
isolated muscles were incubated at 30ºC in a shaking water bath under a constant gas 
phase of 95% oxygen, 5% CO2.      
 
3.1.14.1 Palmitate oxidation in isolated skeletal muscle 
On the day of experiment, mice were fasted for 4 hours and anesthetized with 
intraperitoneal injection of Avertin (0.02 ml/g of body weight). EDL and soleus 
muscles were quickly removed and then incubated in KHB, containing 5 mM glucose 
and 15 mM mannitol for a recovery period of 20 minutes at 30°C, oxygenated with 
95% O2/5% CO2 gas mixture. Muscles were pre-incubated in KHB in the presence or 
absence of MTX (10 µM) for 2 hours, which was followed by analysis of palmitate 
oxidation. For palmitate oxidation assay (Study II) EDL and soleus were incubated in 
KHB containing [
3
H]-palmitate (0.4 µCi/ml) complexed with 20% fatty acid free BSA 
and 0.3 mM cold palmitate for a period of 2 hours with or without AICAR (0.2 mM). 
At the end of the experiment, muscles were taken out of the medium, washed in ice-
cold KHB, briefly blotted on Whatman filter paper, freeze-clamped with aluminium 
tongs snap-frozen in liquid nitrogen and stored at -80°C until further analysis. The 
medium was collected in 1.5 ml eppendorf tubes and stored at -20°C until analysis. For 
the determination of palmitate oxidation, an aliquot (200 µl) of the medium was 
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thoroughly mixed with 800 µl of 10% charcoal slurry (0.02 M Tris-HCl, pH 7.5). The 
mixture was then subjected to centrifugation at 16,000 g for 15 minutes and the 
supernatant (200 µl) was counted for tritium labelled water. The final results are 
normalized per mg of muscle weight. 
 
3.1.14.2 Gene transfer by electroporation into intact mouse muscle  
Adult C57BL/6 mice (20-25 g) were anesthetized by isoflurane. The hindlimbs of the 
mice were shaved using a regular shaving apparatus to visualize the tibialis anterior 
muscle. Hyaluronidase (30 µl of 1 U/µl) was then injected in the tibialis anterior 
muscle through the skin and the mouse was returned to a separate cage for 2 hours. 
Mice were anesthetized by isoflurane using a gas anesthesia machine (Harvard 
Scientific Instruments) and a pool of plasmids (30 µg) encoding either a scrambled 
sequence or shRNA against NT5C1A (SABiosciences, Frederick, MD) was injected in 
the tibialis anterior muscle of each leg through the skin (Study I). Electroporation was 
performed by delivering 220 V/cm of 8 pulses of 20 milliseconds using an ECM 830 
electroporator (BTX, Harvard Apparatus, Holliston, MA).  
 
3.1.14.3 Glucose uptake in intact tibialis anterior muscle 
Seven days after the electroporation procedure, mice were fasted for 4 hours (Study I). 
Thereafter, a bolus of glucose (3 g/kg) was administered by gavage, and [
3
H] glucose 
(4.5 µl of 2-[
3
H]deoxy-D-glucose/ 100 µl of saline/animal, 1 mCi/ml) was administered 
intraperitoneally. Mice were anesthetized 120 minutes after the glucose gavage, and the 
tibialis anterior muscle was dissected and directly frozen in liquid nitrogen for 
subsequent determination of [
3
H]glucose accumulation. Frozen muscle samples were 
homogenized in ice-cold buffer (10% glycerol, 5 mM sodium pyrosulfate, 13.7 mM 
NaCl, 2.7 mM KCl, 1 mM MgCl2, 20 mM Tris (pH 7.8), 1% Triton X-100, 10 mM 
NaF, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin, 0.5 mM sodium vanadate, 1 mM benzamidine, and 1 µM microcystin) for 20 
seconds using a motor-driven pestle. Homogenates were rotated end-over-end for 1 
hour at 4 °C and then subjected to centrifugation at 12,000 g for 10 minutes at 4 °C. 
The supernatant (30 µl) was analyzed by liquid scintillation counting. A portion of the 
remaining supernatant was stored at -80 °C for immunoblot analysis. 
 
3.1.15 Nucleotidase activity assay 
5’-nucleotidase activity was assayed (Study I) as the release of [3H]adenosine from 2-
[
3




H] IMP. An aliquot (20 µl) of homogenate was 
incubated for 15 min at 30°C in a total volume of 50 µl containing 100 mM-Tris-HCl, 2 
mM MgCl2 and 10 mM β-glycero P-Na, with either 2-[
3
H] AMP or 8-[
3
H] IMP (200 
µM of AMP or IMP and 5 µCi of AMP or 1 mCi of IMP, respectively). The incubation 
was terminated by addition of 10 µl of 150 mM ZnSO4, followed by addition of 10 µl 
saturated Ba(OH)2 to precipitate unhydrolyzed AMP or IMP. Samples were placed on 
ice for 10 minutes and subjected to centrifugation (13000 rpm for 15 minutes at 4°C). 
The supernatant was collected for determination of the radioactivity by scintillation 
counting (Belsham et al., 1980). 
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3.1.16 Statistical analysis 
Data are presented as mean ± SEM. Statistical evaluation between groups was 
performed by one-way ANOVA, two-way ANOVA or Students t-test as appropriate 
and as specified in each study. Comparisons were considered statistically significant at 
P < 0.05. Natural log transformation was applied when data were not normally 
distributed. Analyses were performed using either MS Excel version 2010 or SPSS 
version 17.0 (SPSS, Chicago, IL). 
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4 RESULTS AND DISCUSSION 
4.1 MODULATION OF NUCLEOTIDE METABOLISM AS A STRATEGY TO 
MAINTAIN SKELETAL MUSCLE ENERGY HOMEOSTASIS 
4.1.1 Role of 5’-nucleotidases in skeletal muscle metabolism 
Obesity and type 2 diabetes are characterized by an increase in whole-body lipid 
accumulation and decreased insulin-stimulated glucose disposal (DeFronzo and 
Tripathy, 2009). Skeletal muscle is one of the largest organs to utilize the body fuels 
and is a natural target to be affected by the disturbance in substrate metabolism and fuel 
selection in obesity, insulin resistance and type 2 diabetes. Efforts are underway to 
validate new fuel sensing molecules in skeletal muscle to regulate the skeletal muscle 
fuel homeostasis and energy metabolism. One of the molecules which has emerged as a 
critical player in diabetes research and metabolic flexibility is AMPK. In Study I, the 
role of 5’-nucleotidases in skeletal muscle energy metabolism has been dissected by 
linking it to the regulation of AMPK. An alternative strategy to activate the AMPK 



























Figure 6: Working hypothesis to illustrate the role of 5’-nucleotidases (NT5C1A and 
NT5C2) and effect of silencing on AMPK and metabolism in skeletal muscle. 
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4.1.1.1 Effect of 5’-nucleotidases silencing in human and mouse skeletal muscle 
Enzymes involved in cytosolic AMP catabolism, including cytosolic  5’-nucleotidases 
have been implicated in balance of intracellular nucleotide pools (Hunsucker et al., 
2005).  These enzymes are important for maintaining the appropriate levels of AMP 
and ATP and thus may influence AMPK activity. We hypothesized gene silencing of 
5’-nucleotidases enzymes would increase the intracellular availability of AMP relative 
to ATP and may trigger the activation of the AMPK system (Figure 6). Relative mRNA 
expression of NT5C1A and NT5C2 was determined in primary human myotubes. 
NT5C1A mRNA was either low or undetectable, whereas NT5C2 mRNA was readily 
detectable in primary human myotubes. Given that NT5C2 was the only detectable 
enzyme among the two targets studied in human myotubes, gene silencing was directed 
against this enzyme. Although intracellular IMP has not been reported to contribute to 
AMPK activation, IMP is metabolized and converted into adenylosuccinate by 
adenylosuccinate synthetase and is then converted into AMP by adenylosuccinate 
lyase, which may subsequently increase intracellular AMP. Gene silencing of NT5C2 
reduced mRNA expression (Study I, Figure 1A) and protein content (Figure 8) 75% 
and 70%, respectively, followed by a 2-fold increase in the AMP/ATP ratio (Study I, 
Figure 1E). Preliminary data indicate that NT5C1A mRNA expression is increased 1.5-
fold in vastus lateralis muscle from type 2 diabetic patients, compared to normal 
glucose tolerant people (Kulkarni et. al. Unpublished data, Figure 7). The effect of 
NT5C1A silencing was determined in adult mouse skeletal muscle using the 
electroporation technique. Contralateral muscles were transfected with either a 
scrambled sequence or shRNA against NT5C1A.  Gene silencing resulted in 60% 
decrease of NT5C1A protein content (Figure 8) versus the sham-treated contralateral 
muscle, followed by a 17% increase in the AMP/ATP ratio (Study I, Figure 6C).  





Figure 7: NT5C1A and NT5C2 mRNA in human skeletal muscle. NT5C1A and NT5C2 
mRNA expression was determined in skeletal muscle from normal glucose tolerant (NGT) 
and type 2 diabetic (T2DM) subjects. NT5C1A mRNA expression was increased 1.5-fold in 
T2DM, compared to NGT subjects. Conversely, mRNA expression of NT5C2 was similar 
between T2DM and NGT subjects (B). *P < 0.05  
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4.1.1.2 Effect of 5’-nucleotidases silencing on AMPK and ACC phosphorylation  
We hypothesized that siRNA based gene silencing of NT5C2 may increase 
intracellular availability of AMP and IMP, which may alter AMP/ATP ratio and 
increase AMPK activity. NT5C2 silencing in the human cultured myotubes, increased 
basal AMPK phosphorylation 2.0-fold (Figure 8). AMPK phosphorylation was further 
enhanced in NT5C2-silenced myotubes upon AICAR exposure. NT5C2 silencing also 
increased basal ACC phosphorylation 3.6-fold, which was further enhanced in the 
presence of AICAR (Figure 8). In case of mouse skeletal muscle, gene silencing of 
NT5C1A was associated with a 60% increase in AMPK phosphorylation (Figure 8) 
and a 50% increase in ACC phosphorylation (Figure 8), whereas AMPK and ACC 


































Figure 8: Effect of siRNA-mediated silencing of NT5C2 (A) and NT5C1A (B) on protein 
phosphorylation of AMPK and ACC in primary human myotubes or mouse tibialis 
anterior muscle.  
A B 
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4.1.1.3 Effect of 5’-nucleotidases silencing on lipid oxidation and glucose transport 
In cultured human myotubes, NT5C2 silencing increased basal palmitate oxidation 
1.8-fold (Figure 9). NT5C2 silencing did not modify palmitate oxidation under insulin-
stimulated conditions; however, the response to AICAR was enhanced 1.5-fold (Figure 




leading to a decrease 
in malonyl CoA, which releases the inhibitory loop on CPT1 and simulates β-
oxidation of long chain acyl-CoAs in the mitochondrial matrix (Hardie, 1989; Merrill 
et al., 1997; Winder and Hardie, 1996). NT5C2 silencing in the cultured human 
myotubes increased glucose uptake under basal and insulin-stimulated conditions. 
Conversely, AICAR-mediated glucose uptake was unaltered by NT5C2 silencing 
(Figure 9). In vivo electrotransfer to overexpress DNA from endogenous (Bruce et al., 
2009; Mauvais-Jarvis et al., 2002) or mutant proteins (Treebak et al., 2010; Witczak et 
al., 2010) in skeletal muscle has been used to address the role of specific genes in 
signal transduction and metabolism. Taking advantage of this technique, shRNA 
against NT5C1A was used to silence the gene expression in the mouse contralateral 
tibialis anterior muscle. Parallel to the observation in human cultured myotubes, the 
electroporation resulted in ~60% decrease in NT5C1A protein expression (Figure 8), 
increased AMPK and ACC phosphorylation and a ~20% increase in glucose uptake in 




















Another critical enzyme involved in the intracellular availability of AMP is AMP 
deaminase 1 [AMPD1]. AMPD1 plays a major role in regulating cellular AMP levels 
by converting AMP to IMP (Sabina and Mahnke-Zizelman, 2000). Defects in the 
AMPD1 gene increase AMP accumulation in skeletal muscle. The common C34T 
polymorphism in the AMPD1 gene is associated with lower prevalence of type 2 
diabetes, reduced frequency of obesity, and lower systolic blood pressure in people 
with coronary artery disease without heart failure (Safranow et al., 2009), possibly 
Figure 9: Effect of NT5C2 silencing on muscle metabolism: Primary human myotubes were 
transfected with siRNA against a scrambled sequence (white bars) or NT5C2 (black bars) and 
incubated in the absence (Basal) or presence of 120 nM insulin or 1 mM AICAR for 
measurement of glucose uptake. NT5C2 silencing increased basal palmitate oxidation 1.8-fold 
and the response to AICAR was enhanced 1.5-fold. Glucose uptake was increased under basal 
and insulin stimulated condition by 20% and 15% respectively. While silencing of NT5C1A in 
mouse tibialis anterior muscle led to a 20% increase in glucose uptake. Results are mean 
±SEM, *P < 0.05.    
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through increased AMPK activity. Variations in the AMPD1 gene are associated with 
alterations in the metabolic clearance rate of insulin (Goodarzi et al., 2005). 
Conversely, adenylate kinase 1-deficient mice have reduced levels of AMP and exhibit 
decreased contraction- induced AMPK phosphorylation (Hancock et al., 2006) and 
glucose transport (Janssen et al., 2000) in skeletal muscle.  
 
NT5C1A is also expressed in cardiac muscle, where it has a physiological function in 
the generation of adenosine during ischemic conditions and protects the myocardial and 
cerebrovascular systems against ischemia-induced damage (Sala-Newby et al., 1999). 
The family of soluble 5’-nucleotiodases seems to have an increasing clinical potential, 
since 5’-nucleotidases activity is linked with efficacy of certain nucleoside analogues 
that are anti-cancer and anti-viral drugs (Hunsucker et al., 2005). Since these drugs rely 
on their phosphorylation by nucleoside kinases, increased 5’-nucleotidases activity may 
lead to drug resistance (Hunsucker et al., 2005). 
 
In this study a novel role for 5’-nucleotidases in maintaining the intracellular energy 
status via AMPK is highlighted. Alterations in the adenine nucleotide levels may have 
beneficial effects on glucose and energy homeostasis.   
 
 
4.1.2 Methotrexate enhances AICAR mediated AMPK phosphorylation 
and lipid oxidation in skeletal muscle 
Methotrexate (MTX) is a folic acid analog, which has been used for many years to treat 
cancer and rheumatic disease.  Methotrexate is a potent inhibitor of 5-aminoimidazole-
4-carboxamide ribonucleotide formytransferase / inosine monophosphate  
cyclohydrolase (ATIC), which converts intracellular ZMP to IMP. MTX treatment in 
humans (Baggott et al., 1999; Luhby and Cooperman, 1962; Lulenski et al., 1970; 
Morgan et al., 2004) and animals (Baggott and Morgan, 2007) increases excretion of 
ZMP/AICAR metabolite 5-aminoimidazole-4-carboxamide (AICA, Z-base). This 
implies that MTX effectively inhibits ATIC and thereby imposes a metabolic block and 
build-up of ZMP (Cronstein, 2010; Cronstein et al., 1993).  
 
To test the hypothesis that intracellular ZMP accumulation would alter AMPK activity, 
ATIC enzyme activity was inhibited or suppressed by either pretreating the skeletal 
muscle with MTX or by siRNA silencing ATIC in cultured skeletal muscle, 
respectively. We reasoned this strategy would ultimately lead to enhanced sensitivity of 
AMPK towards its activator AICAR, and lead to further AMPK-mediated changes in 
































4.1.2.1 Effect of Methotrexate pretreatment on AICAR-mediated AMPK activation 
in cultured rat and human skeletal muscle.  
MTX treatment in humans and animals increases endogenous production of ZMP 
(Cronstein, 2010; Cronstein et al., 1993) and its metabolites like AICA (Baggott and 
Morgan, 2007; Baggott et al., 1999; Luhby and Cooperman, 1962; Lulenski et al., 
1970). This suggests MTX could activate AMPK and/or reduce the threshold for its 
activation by AICAR. Pretreatment of the L6 myotubes and differentiated human 
skeletal myotubes with MTX (5 µM) for 16 hours, followed by a 5-hour treatment 
with 0.2 mM AICAR, robustly increased AMPK and ACC phosphorylation (Study II, 
Figure 1A, B, 2 A, B). Palmitate oxidation remained unaltered in L6 myotubes treated 
with 0.2 mM AICAR or MTX alone, but MTX-pretreated L6 myotubes when 
stimulated with 0.2 mM AICAR enhanced palmitate oxidation by 15% compared to 
treatment with 0.2 mM AICAR alone (Study II Figure 1C). The MTX-mediated 
reduction in the threshold for AMPK activation could not be considered as an 
idiosyncratic reaction of L6 cell line, since primary human myotubes (Study II, Figure 
2) and murine wild-type EDL and soleus (Study II, Figure 4) displayed essentially the 
same response. 
 
In this study the effects of MTX on signal transduction and metabolism was assessed in 
skeletal muscle. MTX enhanced AMPK signaling in AICAR-treated myotubes and 
isolated murine EDL and soleus, which translated into substantially increased palmitate 
oxidation. These effects were at least partially dependent on the muscle-specific AMPK 
Figure 10: Working hypothesis to illustrate the activation of AMPK by AICAR-P and 
effect of MTX treatment on ATIC mediated intracellular nucleotide metabolism. Inhibition 
of ATIC by MTX or siRNA silencing ATIC potentiated AICAR-mediated AMPK 
phosphorylation in skeletal muscle.  
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γ3 isoform, since MTX was without effect on AMPK signaling and palmitate oxidation 
in AICAR-treated EDL from AMPK γ3-/- mice.  
 
Patients treated with MTX and other disease modifying anti-rheumatic drugs  have 
reduced cardiovascular mortality and an improved metabolic profile, including 
reduction in insulin resistance (Dessein and Joffe, 2006). Data regarding the clinical 
metabolic effects of MTX remains equivocal and it is far from clear whether the 
observed clinical benefit is simply due to immunosupressive and anti-inflammatory 
action of MTX or whether its modulation of AMPK function, observed in cell culture 
of cancer cell, may also contribute. MTX is an inhibitor of ATIC, which is an enzyme 
involved in de novo nucleotide biosynthesis, that imposes a metabolic block, leading to 
intracellular ZMP accumulation, lowering the threshold for AMPK activation. 
 
4.1.3 Targeting 11β-HSD1 for reversal of glucocorticoid action on 
human skeletal muscle cells 
 
Impairments in the glucocorticoid metabolism have been linked to obesity, insulin 
resistance and metabolic syndrome (Chapman and Seckl, 2008; Qi and Rodrigues, 
2007; Walker, 2007; Wang, 2005). The action of glucocorticoids is dependent on an 
enzyme 11β-HSD1, which converts cortisone in an inactive form to cortisol in its 
active form. Local conversion of cortisone to cortisol in target tissues may 
determine tissue-specific roles of glucocorticoids in pathophysiological conditions. 
In this study the intracellular role of 11β-HSD1 in mediating the local 
glucocorticoid effects on skeletal muscle and its impact on glucose and lipid 




















Figure 11: Targeting pre-receptor metabolism of cortisol - Potential treatment for type 2 
diabetes? Detrimental effects of high circulating cortisol on metabolism. 
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4.1.3.1 Effect of glucocorticoids on skeletal muscle substrate metabolism: role in 
shift of metabolism 
The effects of chronic exposure of glucocorticoids i.e, cortisone (inactive) and cortisol 
(active) were determined on skeletal muscle metabolism by assessing glucose and lipid 
metabolism. Glucose metabolism was assessed by measuring glucose uptake (Figure 
12) and glycogen synthesis (Study III, Figure 1C), while the lipid metabolism was 
assessed by measuring palmitate oxidation (Study III, Figure 1D). Chronic exposure of 
skeletal muscle to active or inactive glucocorticoids had a negative impact on glucose 
metabolism, indicating a shift in metabolism from glucose to lipid oxidation. This also 
indicated the presence of a functioning machinery to convert inactive cortisone to 
active cortisol, since the treatment of cells with inactive cortisone paralleled the effect 

















4.1.3.2 Role of 11βHSD1 in glucocorticoid-mediated effects on skeletal muscle 
metabolism 
The pre-receptor metabolism of the glucocorticoids determine the tissue specific 
sensitivity, which is also partly regulated by enzyme 11β-HSD1 that converts inactive 
cortisone to active cortisol (Salehzadeh et al., 2009). Increased adipose tissue 11β-
HSD expression has been observed in obesity, which may lead to increased local 
glucocorticoid signaling (Stimson et al., 2009). Transgenic mice overexpressing HSD1 
in either liver or adipose tissue have features resembling that noted in the metabolic 
syndrome (Paterson et al., 2004) while transgenic deletion of 11β-HSD1 prevents 
adverse metabolic complications of obesity (Kotelevtsev et al., 1997).   
 
The role of 11β-HSD1 in the skeletal muscle glucocorticoid-mediated changes in the 
metabolism was determined. Chronic exposure of cultured myotubes to either 
cortisone or cortisol resulted in a 2-fold increase in mRNA (Study III, Figure 2A) 
expression and 4-fold increase in protein (Figure 13) expression of 11β-HSD1. This is 
in agreement with earlier observations exhibiting positive effects of glucocorticoids on 
Figure 12: Effect of glucocorticoid 
exposure on skeletal muscle glucose 
uptake. Primary cultures of human 
skeletal muscle were exposed to 0.5 
μM cortisol or 0.5 μM cortisone for 
eight days. Insulin-stimulated glucose 
uptake was determined. Results are 
mean ± SEM. Basal (open box), 
insulin (closed box),*P < 0.05, **P < 
0.01 vs. control basal, # P < 0.05 vs. 
basal for each condition.  
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HSD1 expression in cultured human skeletal muscle (Whorwood et al., 2002) and 
other cell types (Hammami and Siiteri, 1991; Sun and Myatt, 2003). These previous 
observations indicate increased skeletal muscle glucocorticoid sensitivity.   siRNA 
against 11β-HSD1 was used to reverse the glucocorticoid-mediated effects on 
metabolism. siRNA against 11β-HSD1 prevented the cortisone, but not cortisol-
mediated reduction in glucose incorporation into glycogen (Study III, Figure 3A). The 
siRNA-mediated reduction of 11β-HSD1 decreased cortisone-, but not cortisol-
mediated increases in lipid oxidation (Study III, Figure 3B); rather an unexpected 
increase in cortisol-mediated palmitate oxidation was observed. Using a 
pharmacological inhibitor against 11β-HSD1, similar results on metabolism was 



















4.1.3.3 Glucocorticoid-mediated changes in gene expression in human skeletal 
muscle 
This study focused on the direct effects of glucocorticoids on primary human skeletal 
muscle cells. Expression of key regulatory genes involved in glucose and lipid 
metabolism remained unaltered after chronic exposure of the cultured myotubes to 
either 0.5µM cortisone or cortisol (Study III, Table 2). However, expression of PDK4 
mRNA and protein was increased after an 8 day treatment of human cultured 
myotubes with either cortisone or cortisol (Study III, Figure 4A). A key mechanism in 
regulation of tissue fuel selection is at the level of mitochondrial pyruvate 
dehydrogenase complex, an enzyme that catalyzes the conversion of pyruvate to acetyl 
CoA, which is also regulated negatively by PDK enzymes. We determined the role of 
PDK4 in glucocorticoid-mediated effects on skeletal muscle. Gene silencing of PDK4 
by siRNA prevented the cortisol-mediated reduction in glycogen synthesis (Study III, 
Figure 4C), suggesting PDK4 may play a key role in the cortical-mediated metabolic 
shift in substrate utilization in human skeletal muscle. Our findings are in agreement 
Figure 13: Effect of HSD1 siRNA 
on protein expression. Myotubes 
were exposed to glucocorticoids as 
described in Figure 12. Myotubes 
were transfected with siRNA against 
a scrambled sequence (open box) or 
11β-HSD1 (closed box) and 11β-
HSD1 protein content was 
determined. Upper panel shows 
representation of immunoblot of 11β-
HSD1 protein content. Scr: 
Scrambled siRNA, 11β-HSD1: siRNA 
targeted against 11β-HSD1. Results 
are mean ± SEM. *P < 0.05 
transfected myotubes vs. scramble-




with previous findings reporting an enhanced glucose oxidation in isolated skeletal 
muscle of mice with targeted deletion of PDK (Jeoung and Harris, 2008).  
 
Collectively, these data indicate that PDK4 plays a key role in mediating the effects of 
cortisol to attenuate skeletal muscle glucose utilization, and subsequent increase in 
lipid utilization. 11β-HSD1 could be a target molecule to overcome the deleterious 
effects of cortisone-mediated shift in the metabolism. Pre-receptor metabolism of 
glucocorticoids thus, could be a novel strategy in treatment of diabetes and obesity. 
 
4.1.4 Mitochondrial regulators of fatty acid metabolism as targets for 
muscle fuel homeostasis 
The mitochondria is the aerobic powerhouse of the cell, since it converts and 
conserves energy obtained from various metabolic processes such as oxidation of 
the macronutrients and thus contributing to the overall energy balance. Skeletal 
muscle mitochondrial activity is a controlled process, which is governed by a 
variety of internal stimuli. The ability of the mitochondria to sense the metabolic 
perturbations and accordingly adapt to maintain cellular energy homeostasis, places 
it at a center stage in treatment of diabetes, obesity and metabolic syndrome. 
Moreover, mitochondrial proteins such as PDK4, CPT1 are located at the metabolic 
flux points playing key roles in fuel selection and metabolic flexibility (Figure 14). 
Impairments in mitochondrial metabolism and diminished oxidative capacity is 
directly associated with impairments in skeletal muscle insulin signaling, 
accumulation of intramyocellular triglycerides and progression of type 2 diabetes 
and obesity (Kelley et al., 1999). The diminished mitochondrial capacity in type 2 
diabetics could be due to changes in the expression profile of the key genes such as 
PDK2, PDK4, CPT1 and MCD located at critical metabolic flux points governing 
mitochondrial fatty acid metabolism. The aim of this study was to profile the 
expression pattern of PDK4, PDK2, CPT1b, MCD in skeletal muscles obtained 















































4.1.4.1 Skeletal muscle gene expression profile of key mitochondrial regulators of 
substrate switching  
Type 2 diabetes mellitus is associated with abnormal substrate metabolism, raising the 
possibility that alterations in the expression of mitochondrial enzymes controlling lipid 
uptake and metabolism may by altered. Skeletal muscle expression of key 
mitochondrial genes that orchestrate the switch of substrate utilization between glucose 
and lipid sources was determined. mRNA expression of PDK4, PDK2, CPT1 and 
MCD was assessed in skeletal muscle from normal glucose tolerant and type 2 diabetic 
patients matched for age and body mass index [BMI]. PDK4 mRNA expression was 
increased 70% in skeletal muscle from type 2 diabetic patients compared to normal 
glucose tolerant subjects (Study IV, Figure 1A). Skeletal muscle mRNA expression of 
PDK2 and MCD was increased 50% in type 2 diabetic patients (Study IV, Figure 1B, 
and D).  
 
Elevated PDK4 gene expression has been associated with various clinical 
manifestations, such as high circulating lipids (Sugden and Holness, 2006). In rodents, 
Figure 14: Regulation of glucose and fatty acid metabolism in skeletal muscle. 
Substrate utilization is controlled at several steps. The gate keeper proteins such 
as PDK4, PDK2, CPT1, MCD and AMPK occupy central roles in regulation of 
the substrate switching and muscle metabolism.   
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a 4-week high fat diet increases skeletal muscle PDK4 expression (Holness et al., 
2000). However in normal glucose tolerant subjects and type 2 diabetic patients plasma 
triglyceride levels are unaltered. Thus in this cohort, PDK4 mRNA expression is 
unrelated to circulating triglycerides. This discrepancy to previous results may be due 
to the fact that a subset of the type 2 diabetic cohort was treated with cholesterol 
lowering drugs that might have masked the previously observed relationships. 
However, a significant correlation was observed between PDK4 mRNA expression and 
BMI (Figure 15), highlighting the close relationship between expression of 
mitochondrial genes related to lipid metabolism and body mass index. A close positive 
relationship was also observed between PDK4, PDK2, MCD and CPT1, further 
strengthening the observation that this cluster of genes were similarly coordinated and 






















4.1.4.2 Evidence of epigenetic regulation of PDK4 promoter and gene expression 
The methylation status of cytosines in the PDK4 promoter region was determined in 
genomic DNA extracted from skeletal muscle biopsies obtained from type 2 diabetic 
and normal glucose tolerant participants. DNA methylation is a major epigenetic 
modification that regulates the gene expression by altering the accession of the 
transcription factors to the promoter regions in the DNA (Cedar and Bergman, 2009). 
The PDK4 promoter in skeletal muscle obtained from type 2 diabetic patients was 
found to be hypo-methylated compared to skeletal muscle of normal glucose tolerant 
volunteers, with the mRNA expression being inversely regulated (Study IV, Figure 3A, 
B). Hypomethylation of the PDK4 promoter in skeletal muscle of type 2 diabetic 
patients is coincident with an impaired response of PDK4 mRNA after exercise. 
Evidence is emerging that epigenetic modifications through DNA methylation may 
Figure 15: A significant correlation was observed between PDK4 mRNA expression and 
body mass index.   
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contribute to the increased risk and development of metabolic disease by modifying the 
expression of genes controlling whole body energy and glucose homeostasis (Barres et 
al., 2009; Klose and Bird, 2006). Increased promoter methylation of peroxisome 
proliferator-activated receptor 1α (PGC1α), another key regulator of mitochondrial 
activity and metabolism, has been reported from skeletal muscle of individuals with 
impaired glucose tolerance or type 2 diabetes mellitus (Barres et al., 2009).  Evidence 
for the effect of nutrition and metabolic status of an individual on the epigenetic 
regulation in type 2 diabetes (Pembrey et al., 2006) raises the possibility that epigenetic 
modifications of genomic DNA may contribute to the development of metabolic 
diseases.   
 
4.1.4.3 Effect of life style modification on anthropometry and skeletal muscle mRNA   
The effect of a 4-month lifestyle intervention on anthropometry and mRNA expression 
was determined (Figure 16). The intervention involved 4 hours of Nordic walking per 
week. Muscle biopsies were obtained from study participants before and after the 4 
month intervention. The lifestyle intervention was accompanied by weight loss, 
decrease in waist circumference and BMI in both normal glucose tolerant volunteers 
and type 2 diabetic patients (Table 1) while decrease in a 2-hour plasma glucose levels 
was observed only in type 2 diabetic patients (Table 1). Skeletal muscle PDK4 mRNA 
expression was increased only in the normal glucose tolerant subjects in response to 
the lifestyle intervention, but not in type 2 diabetic patients (Study IV, Figure 4A). 
This differential response between normal glucose tolerant humans and type 2 diabetic 
patients could be due to a higher compliance with the exercise program in normal 
glucose tolerant subjects or due to an inherent difference in exercise-dependent gene 
regulation in type 2 diabetic patients. Marked reduction of skeletal muscle PDK4 
expression is observed in morbidly obese patients who underwent gastric bypass 
surgery (Rosa et al., 2003) and a decrease in PDK4 expression has been associated 
with increased insulin sensitivity (Rosa et al., 2003). Weight loss after the exercise 
intervention in the present study was modest, yet PDK4 mRNA expression was 
elevated in normal glucose tolerant subjects after intervention. In contrast, skeletal 
muscle mRNA expression of PDK2, CPT1 and MCD remained unaltered after the 












































Table 1: Anthropometric measurements and metabolic parameters in normal glucose 
tolerant (NGT) and type 2 diabetic subjects (T2D). Data are presented as means ± SEM. 
BMI indicates body mass index; BG, blood glucose; SBP, systolic blood pressure; DBP, 
diastolic blood pressure. *Significant at P < 0.01 level  
 
Figure 16: Effect of lifestyle modification on overall health and fitness. In this exercise 
intervention Study, both normal glucose tolerant and type 2 diabetic male and female subjects 
were recruited and divided in two groups. One group was instructed to increase their physical 
activity by 5 hours/ week for four months by performing Nordic walking exercise while the 
other to maintain their habitual lifestyle. Blood glucose, VO2 max, anthropometric 
measurements and a muscle biopsy was collected both before and after the intervention.      
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4.1.4.4 Effect of exercise mimetics on cultured human skeletal muscle cells 
In an attempt to dissect the influence of factors that are altered in response to exercise, 
mRNA expression of PDK4, PDK2, CPT1b and MCD was determined in cultured 
human myotubes after exposure to different agents including caffeine, AICAR and 
palmitate. These factors were selected to mimic some of the in vivo changes noted 
following exercising intervention. PDK4 mRNA expression was robustly increased 
after incubation with caffeine or palmitate (Study IV, Figure 5A). PDK2 mRNA 
expression was increased only after incubation with caffeine. CPT1b mRNA 
expression was markedly increased by palmitate exposure (Study IV, Figure 5B), 
while both caffeine or palmitate increased the MCD mRNA expression (Study IV, 
Figure 5C, D). However, mRNA expression of all four genes studied was unaltered 




The overall goal of this study was to identify and validate novel molecules involved in 
maintaining the metabolic flexibility of skeletal muscle. 
 
 In Study I, the role of 5’-nucleotidases in maintaining overall skeletal muscle 
metabolism and energy homeostasis is highlighted. Targeting skeletal muscle 
5’-nucleotidases (NT5C1A and NT5C2) could be one potential strategy to 
activate AMPK and thus mediate the beneficial effects of AMPK in promoting 
skeletal muscle metabolic flexibility.   
 
 In Study II, evidence that MTX treatment results in inhibition of   enzymes 
involved in nucleotide metabolism leading to a reduction in the threshold for 
AMPK activation; thus potentiating AICAR-stimulated AMPK activity is 
provided. 
 
 In Study III, 11β-HSD1 is validated as a potential skeletal muscle anti-diabetic 
target. siRNA-mediated reduction of 11-βHSD1 prevents the effects of 
cortisone but not cortisol on metabolism via a PDK4-dependent mechanism in 
skeletal muscle.  
 
 In Study IV, evidence that skeletal muscle expression of mitochondrial 
regulators of fatty acid metabolism reflects metabolic dysfunction in type 2 
diabetes is provided. Skeletal muscle expression of PDK4 and related genes 
regulating mitochondrial function reflects alterations in substrate utilization and 
clinical features associated with type 2 diabetes mellitus. Furthermore, 
hypomethylation of the PDK4 promoter in skeletal muscle of type 2 diabetic 
patients was coincident with an impaired response of PDK4 mRNA after 
exercise. 
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6 CONCLUSIONS  
The results presented in this thesis highlight novel molecular strategies to bypass 
impairments in skeletal muscle glucose and lipid metabolism and restore skeletal 


























In skeletal muscle, AMPK can be activated by metabolic stress such as hypoxia, 
exercise and glucose deprivation. This thesis presents novel strategies to activate 
AMPK by altering select enzymes of nucleotide metabolism including 5’-nucleotidases 
and ATIC. Silencing of 5’-nucleotidases enzymes, NT5C1A and NT5C2 by RNAi 
technology activated the AMPK system in skeletal muscle by altering the cellular 
AMP: ATP ratio. Pre-treating the skeletal muscle with MTX rendered AMPK more 
sensitive to endogenous and/or exogenous activator [AICAR] via inhibition of ATIC. 
Our results indicate that targeting enzymes controlling specific steps in intracellular 
nucleotide metabolism could be a novel approach to activate the AMPK system and 
mediate beneficial metabolic effects. 
 
Skeletal muscle mRNA expression of key enzymes involved in substrate metabolism, 
including PDK4, PDK2 and MCD are altered in skeletal muscle of type 2 diabetes 
mellitus patients. Increased expression of PDK4 mRNA was coincident with decreased 
PDK4 promoter methylation, indicative of altered epigenetic regulation. How altered 
Figure 17: Summary of molecular mechanisms which maintain cellular glucose and lipid 
metabolism investigated in this thesis.  
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PDK4 promoter methylation affects muscle PDK4 expression requires further 
investigation. Low intensity exercise resulted in increased PDK4 mRNA expression 
only in healthy subjects, but not in type 2 diabetic patients reflecting inflexibility to 
adapt to exercise responses. Thus it is tempting to speculate that epigenetic alterations 
underlie the impaired exercise-induced response.  
 
Evidence that PDK4 plays a pivotal role in mediating deleterious effects of 
glucocorticoid excess on skeletal muscle glucose metabolism is provided. Thus PDK4 
plays a central role in directing muscle nutrient metabolism. Direct manipulation of 
PDK4 expression in human skeletal muscle is a challenging proposition. However, we 
have validated that inhibition of the enzyme 11β-HSD1, markedly reducing local 
glucocorticoid signaling, inhibits glucocorticoid-mediated induction of PDK4.  Further 
studies are warranted to explore different approaches to regulating skeletal muscle 
PDK4 expression.  
 
Taken together, results presented in this thesis provide evidence for novel mechanisms 
which act as entry points for therapeutic interventions for the treatment of insulin 
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7 FUTURE PERSPECTIVES 
The primary aim of this thesis was to investigate key molecular regulators involved in 
skeletal muscle glucose and lipid metabolism. Therapeutic strategies to enhance whole-
body lipid or glucose metabolism may improve insulin sensitivity and energy 
homeostasis in type 2 diabetic patients.  
 
The energy sensing enzyme AMPK has been the focus of many investigation and is 
considered an attractive anti-diabetic target. A major aim of this thesis was to delineate 
the mechanisms governing the AMPK activity in skeletal muscle. One challenge is to 
develop a drug that is specific to AMPK. The question remains whether a drug that 
specifically activates AMPK would yield therapeutic effects without having deleterious 
side effects. AICAR, the most widely used AMPK activator has positive effects on 
metabolism. However, this drug is a long way from clinical treatment of insulin 
resistance and type 2 diabetes, since it is not specific to AMPK and it activates several 
other kinases. One way to activate the AMPK system as highlighted in this thesis 
would be to alter the expression of AMP-metabolizing enzymes, such as 5-
nucleotidases and ATIC. Silencing of 5’-nucleotidases, NT5C1A and NT5C2 in rodent 
muscle and human skeletal muscle cell culture respectively increased AMPK and ACC 
phosphorylation and enhanced glucose and lipid metabolism, indicating their role in 
restoring skeletal muscle energy homeostasis. These results provide proof-of-principle 
that skeletal muscle specific inhibitors of 5’-nucleotidases enzymes may be beneficial 
to improve metabolism in type 2 diabetes. Since this approach was skeletal muscle 
specific, deleterious cardiac effects could be avoided. This thesis investigated the 
transient effects of inhibition of 5´-nucleotidases. Future studies to assess the 
consequence of long-term inhibition of 5’-nucleotidases enzymes is warranted.  
 
Studies in this thesis were designed to test hypothesis that the AMPK system can be 
activated by lowering the threshold of AMPK activation to render AMPK more 
sensitive to endogenous and/or exogenous activators. In this way, one could expect to 
have a maximum AMPK activation with administration of relatively lower dose of the 
activator compound and curtail unwanted side effects. This strategy has been partly 
demonstrated in this thesis by pre-treating skeletal muscle with MTX and inhibiting 
ATIC (Study II). MTX is used as an anti-rheumatic drug, and patients with MTX 
treatment have reduced cardiovascular mortality, improved metabolic profile and 
improved insulin sensitivity. Co-treatment with multiple chemical compounds that have 
complementary mechanisms of action or with compounds that elicit effects through 
different pathways, often provide insight towards more effective intervention. The 
development of more selective inhibitors of ATIC may improve efficacy of therapeutic 
intervention for treatment of obesity and diabetes.  
 
A second focus of this thesis was to identify and validate metabolic “gate keeper” 
molecules; i.e. key molecules regulating the shift in substrate metabolism. In obesity, 
expression of 11β-HSD1 is increased and this can increase local glucocorticoid 
signaling. A central role of PDK4 in the cortisol-mediated shift in cellular metabolism 
was highlighted. The effects of glucocorticoids to increase lipid oxidation and reduce 
glucose metabolism appears to be dependent on induction of PDK4 expression.  
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Increased PDK4 expression would inhibit glucose oxidation and this may be an 
important adaptive mechanism to conserve glucose in the fasting state, when glucose is 
scarce. Insulin acts to suppress PDK4 in the fed states when glucose is abundant. 
Increases in muscle PDK4 expression with type 2 diabetes may be largely due to 
reduced insulin action (i.e. insulin resistance or relative insulin deficiency), rather than 
to increases in circulating FFAs (Kim et al., 2006). Whether an increase in expression 
is a cause or a consequence of insulin resistance remains to be determined. This key 
question remains to be addressed to further design therapeutic interventions against 
type 2 diabetes mellitus. 
 
Physical activity and exercise have beneficial effects on substrate metabolism and play 
crucial role in prevention and management of type 2 diabetes. Nevertheless, exercise 
intervention may not be feasible for all subjects with type 2 diabetes, and in some cases, 
a combination of exercise and pharmacological intervention could prove to be 
efficacious. Thus further studies on skeletal muscle insulin sensitivity are necessary to 
validate novel targets for the development of drugs in attempt to combat the world wide 
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